Search

Discover how a watch-and-wait approach to treating rectal cancer can help people avoid surgery and preserve normal body functions.

… Tuesday, January 15, 2019 Summary The biggest study of its kind in North America finds a watch-and-wait strategy can have excellent long-term results for some people with rectal cancer. Cancers of the colon and rectum are often grouped together as colorectal cancer because both are part of the large

With the help of machine learning, computational biologists are learning to predict how cancers will evolve.

… Wednesday, June 23, 2021 From amoebas to zebras, all living things evolve. They change over time as pressures from the environment cause individuals with certain traits to become more common in a population while those with other traits become less common. Cancer is no different. Within a growing tumor

Learn about gastrointestinal distress, one of the more common side effects of immunotherapy.

… Thursday, January 31, 2019 Summary One of the most common immunotherapy side effects is gastrointestinal distress. MSK gastroenterologist David Faleck explains why this happens and how to find relief. Chances are that you have heard some buzz about immunotherapy . This type of cancer treatment trains

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences.

… Thursday, September 14, 2023 Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024  Breakthrough Prize in Life Sciences

Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer, according to a new study. Results from the phase III "OCEANS" trial were presented today by the lead author, Carol Aghajanian, MD, of Memorial Sloan Kettering Cancer Center, at the 2011 annual meeting of the American Society of Clinical Oncology.

… Saturday, June 4, 2011 Bevacizumab (Avastin®) in combination with chemotherapy resulted in a clinical benefit for patients with recurrent ovarian cancer , according to a new study. Results from the phase III “OCEANS” trial were presented today by the lead author, Carol Aghajanian, MD , of Memorial Sloan

Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials.

… Friday, September 21, 2018 Today Memorial Sloan Kettering (MSK) announced the appointment of a task force that will assess MSK policies and processes for reporting and managing outside activities and industry-supported clinical trials. The task force was announced in a statement from MSK President and

Learn how experimental vaccine might train the immune system to prevent pancreatic cancer from returning.

… Monday, June 10, 2024 Pancreatic cancer has long been a forbidding disease. While the five-year survival rate has inched upward in recent years, it remains quite low — about 12%. But surgeon-scientist Vinod Balachandran, MD , has focused on a glimmer of hope: A small percentage of people manage to beat

Discover what Memorial Sloan Kettering contributed to the science and medicine of x-rays.

… Tuesday, October 4, 2016 Summary Since 1902, Memorial Sloan Kettering has been a pioneer in the science and medicine of x-rays, developing many of the radiation techniques in use today. In a previous post , we recounted the history of radium therapy at Memorial Sloan Kettering. Radium, a naturally occurring

Investigators at Memorial Sloan Kettering Cancer Center, along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large-scale, multi-institutional study of prostate cancer death after standard treatment to remove the prostate since PSA screening has become widely used as a method to screen for the disease.

… Monday, July 27, 2009 Investigators at Memorial Sloan Kettering Cancer Center (MSKCC), along with collaborating teams at the Cleveland Clinic and the University of Michigan, have completed the first large- scale, multi-institutional study of prostate cancer death after standard treatment to remove the

Learn about insights that could lead to a new class of drugs against cancers caused by RAS gene mutations.

… Wednesday, October 30, 2024 Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS , and HRAS . RAS-family mutations are associated with numerous types of cancer. KRAS mutations are found in pancreatic cancer ,  colorectal cancer ,